Clinical Trial

A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal Function

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the pharmacokinetics and safety of golcadomide (BMS-986369) in matched healthy participants with normal renal function, adult participants with severe renal impairment, and participants with end-stage renal disease.
Trial Details
NCT Number NCT07763418
Lead Sponsor Bristol-Myers Squibb
Conditions Kidney Failure, Chronic
Enrollment 30 participants
Start Date 2026-08-24
Primary Completion 2026-12-14 (estimated)
Study Completion 2026-12-28 (estimated)
Updated on ClinicalTrials.gov 2026-08-13